Source: Annual Congress 2013 –Studies of asthma in man
Disease area: Airway diseases

Abstract

Background: Efficacy and safety of sublingual immunotherapy tablets (SLIT) of house dust mite (HDM) allergen extracts have been demonstrated in patients with HDM allergic rhinitis.
Aims and objectives: Here we report their safety and tolerability in patients with HDM-associated allergic asthma.
Methods: Adults with a history of HDM allergic asthma (≥ 1 year) controlled with therapies consistent with GINA treatment step 2, 3 or 4, a positive skin prick test to HDM, and HDM-specific serum IgE ≥ 0.7 kU/L were eligible for this DBPC study. Participants, stratified according to GINA treatment step at screening, were randomised 3:1 within dose-regimen groups to receive either increasing doses of SLIT tablets of HDM allergen extracts or placebo for 10 consecutive days. Four dose regimens with progressive incremental dosing from 300IR to 1000IR (IR=Index of Reactivity) were studied sequentially. Adverse events (AEs), physical examination, vital signs, spirometry, ECG and laboratory tests were analysed descriptively.
Results: 63 patients received either 300IR (n=11), 500IR (n=12), 800IR (n=12), 1000IR (n=12) or Placebo (n=16). No deaths, serious AEs, anaphylaxis, epinephrine use, or treatment-related asthma exacerbation were reported. The most common AEs were mild oropharyngeal reactions which resolved without treatment. A similar safety profile was observed in patients regardless of asthma treatment step at screening or the dose administered.
Conclusion: Sublingual tablets of HDM allergen extracts administered with ascending doses up to 1000IR were well tolerated in patients with HDM-associated allergic asthma and are suitable for further clinical evaluation.

Rating:

Share or cite this content

Citations should be made in the following way:
R. K. Zeldin, P. Demoly, P. Betting, P. Rodriguez, A. Racaud, M. Le Gall (Antony, Montpellier, Paris, France). Sublingual tablets of house dust mite allergen extracts: Results of a phase I study in adults with mite-associated allergic asthma. Eur Respir J 2013; 42: Suppl. 57, 3157

Member's Comments

No comment yet.

Related content which might interest you: High doses of sublingual tablets of house dust mite allergen extracts: Lung function assessment in a phase I study in adults with mite-associated allergic asthma Source: International Congress 2015 – Immune aspects of asthma and other airway diseases Year: 2015 Collaborative treatment with variety of dust mites allergic in standardized dermatophagoides pteronyssinus allergen immunotherapy Source: International Congress 2016 – Clinical studies in asthma and immunology Year: 2016 Safety of 5-grass pollen extract sublingual tablet in patients with grass pollen-induced allergic rhinoconjunctivitis and concomitant intermittent asthma: A pooled analysis Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Safety of subcutaneous immunotherapy with standardized extracts of house dust mite in allergic asthmatic subjects Source: Eur Respir J 2002; 20: Suppl. 38, 57s Year: 2002 LSC 2014 abstract - Influenza-induced exacerbation in a murine chronic house dust mite (HDM) asthma model Source: International Congress 2014 – Exploring molecular mechanisms of allergy and asthma in animal models Year: 2014 Association between Th2 biomarker levels and efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Efficacy of specific allergy vaccination in house dust mite asthma Source: Eur Respir J 2005; 26: Suppl. 49, 465s Year: 2005 Prevention of paediatric asthma and allergy by reduction of house dust mite content Source: Eur Respir J 2001; 18: Suppl. 33, 287s Year: 2001 Late Breaking Abstract - Budget impact of introducing 12SQ HDM SLIT-tablet for house dust mite allergic asthma in Spain Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019 Sublingual immunotherapy is an established therapy for house dust mite sensitive allergic rhinitis and/or asthma Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007 Clinical efficiency of sublingual and subcutaneous allergenspecific immunotherapy with household dust mite allergen in patients with persistent allergic rhinitis Source: Eur Respir J 2006; 28: Suppl. 50, 438s Year: 2006 Bacteria and mould components in house dust and children's allergic sensitisation Source: Eur Respir J 2007; 29: 1144-1153 Year: 2007 Omalizumab is equally effective in persistent allergic oral corticosteroid-dependent asthma whether due to seasonal allergens or to perennial allergens Source: International Congress 2015 – Asthma and lung immunology Year: 2015 House dust mite sublingual immunotherapy reduces type 2 biomarkers in allergic asthma Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020 OPURIT: Omalizumab-protected ultra rush specific immunotherapy in severe asthmatic patients with house dust mite allergy Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011 Effects of airborne pollen levels on drug consumption for seasonal allergic rhinoconjunctivitis: A ten-year French study Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 Diagnostic utility of serum periostin for house dust mite sublingual immunotherapy response in allergic rhinitis Source: Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials Year: 2021 Dynamic change of house dust mites and its components- sIgE and sIgG4 in specific immunotherapy Source: International Congress 2014 – Intervening in allergic asthma Year: 2014 The effect of anti-mite mattress covers on mite allergen levels in the PIAMA (prevention and incidence of asthma and mite allergy) study Source: Eur Respir J 2001; 18: Suppl. 33, 321s Year: 2001 House dust mite (HDM) avoidance and treatment of severe childhood asthma Source: Eur Respir J 2003; 22: Suppl. 45, 314s Year: 2003